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Severe Peripheral Neuropathy From Treatment With Arsenic 
Trioxide in a Patient Suffering From Acute  
Promyelocytic Leukemia
Soren Niemi Helsoa, e, Anne Stidsholt Rouga, b, c, Morten Morkd, 
 Eva Futtrup Makstena, b, Marianne Tang Severinsena, b, c
Abstract
Treatment with arsenic trioxide (ATO) and all-trans retinoic acid 
(ATRA) is standard treatment for patients suffering from acute promye-
locytic leukemia (APL). Peripheral neuropathy is a common sign of 
arsenic poisoning but reports of peripheral neuropathy from patients 
treated with ATO for APL are limited. We here present a case of a wom-
an treated with standard regimes of ATRA-ATO for APL, who subse-
quently developed severe peripheral neuropathy from ATO poisoning.
Keywords: Arsenic trioxide; Leukemia; Acute promyelocytic leuke-
mia; Peripheral neuropathy; Arsenic poisoning
Introduction
Acute promyelocytic leukemia (APL) is an extremely life-
threatening neoplasm with severe coagulopathy at diagnosis, 
and is a distinct subtype of acute myeloid leukemia, charac-
terized by the PML-RARA fusion gene generated from the 
reciprocal t(15;17)(q22;q21) chromosomal translocation. The 
disease is important to recognize, as patients rapidly deterio-
rate without proper treatment [1]. Since the advent of all-trans 
retinoic acid (ATRA) in combination with chemotherapy, and 
lately in combination with the inorganic arsenic compound, ar-
senic trioxide (ATO), the cure rate has increased tremendously. 
Today, ATRA in combination with ATO is standard treatment 
[1]. However, this so-called chemo-free treatment is not with-
out side effect, i.e., ATO is a highly toxic chemical drug natu-
rally present in various substances with a number of applica-
tions exploiting its toxicity [2].
Acute poisoning from inorganic arsenic in humans affects 
all organ systems. Symptoms include vomiting, profuse diar-
rhea, toxic cardiomyopathy, pulmonary edema, seizures and, 
ultimately, death. In the clinical setting, especially QTc-pro-
longation and hepatotoxicity must be addressed and carefully 
monitored during treatment with ATO [2, 3]. Lethal poisoning 
from inorganic arsenic, such as ATO, occurs at dosages from 
1.0 to 3.0 mg/kg, if taken orally as a bolus. If exposed over a 
shorter period of time (14 days), the lethal dose is estimated to 
be about 0.6 mg/kg/day; whereas exposure > 365 days leads 
to fatal poisoning in dosages from 0.01 to 0.1 mg/kg/day [4].
Chronic, non-lethal levels of inorganic arsenic poisoning 
have different characteristics. Dermatological changes are seen 
in the form of hyperpigmentation, palmar and solar keratosis 
and Mees’ lines on finger and toe nails. Neurological symp-
toms include peripheral neuropathy mimicking Guillain-Barre 
syndrome, cognitive impairment, confusion and memory loss 
[5]. Other symptoms involve the gastrointestinal, genitou-
rinary and the respiratory and cardiovascular systems [2, 3]. 
These manifestations of chronic, non-lethal arsenic poisoning 
occur at levels of 0.001 to 0.1 mg/kg/day, if exposed to inor-
ganic arsenic > 365 days [4].
With the addition of ATO to the treatment of patients suf-
fering from APL, clinicians must be aware of the potential side 
effects. We here report a case of a previously healthy woman 
who was diagnosed with APL and treated with ATRA-ATO 
who subsequently developed invalidating polyneuropathy.
Case Report
A 63-year-old, previously healthy woman was referred to the 
Department of Hematology at Aalborg University Hospital 
in June 2018 due to leucopenia and anemia. Blood samples 
showed hemoglobin levels of 11.1 g/dL, platelets of 154 × 
109/L, leucocytes of 1.5 × 109/L, D-dimer of 15.9 mg/L, lactate 
dehydrogenase of 191 U/L and fibrinogen of 156 mg/dL. Bone 
marrow examination revealed 50% promyelocytes and fluores-
cence in situ hybridization (FISH) was positive of PML-RARA 
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fusion gene, pathognomonic for APL. Induction treatment with 
ATRA-ATO was started; i.e., ATO 0.3 mg/kg intravenously day 
1 - 5, and 0.25 mg/kg day 8, 11, 15, 22, 25, 29, 32 combined 
with ATRA 22.5 mg/m2 for day 1 - 32 (induction line). Bone 
marrow biopsy on day 31 showed complete remission (CR) 
by morphology and cytogenetics and a reduction of measur-
able minimal residual disease (MRD) to a level of 0.1%. The 
patient experienced dysesthesia on her palms and plantar faces 
of feet but had no other side effects. Consolidation treatment 
included ATO of 0.3 mg/kg of day 1 - 5, in the first week, 
and 0.25 mg/kg two times per week for 3 consecutive weeks 
followed by 4 weeks without ATO combined with ATRA for 
day 1 - 14 and day 29 - 42. After 1 week of consolidation she 
developed a generalized rash, nausea and vomiting. She was 
administered cortisone and responded promptly, and the treat-
ment was continued (i.e., 0.25 mg/kg two times per week for 3 
consecutive weeks followed by 4 weeks of no ATO but ATRA 
as described above). In total, she received the induction treat-
ment counting 285 mg of ATO followed by one consolidation 
treatment counting 262 mg of ATO. Bone marrow examination 
following the first consolidation course showed complete mo-
lecular remission of APL. The treatment with ATO was discon-
tinued and only one of four courses of consolidation treatment 
with ATRA was given. However; the dysesthesia progressed 
over the following month and included severe paresthesia and 
pronounced, generalized muscular fatigue, among others lead-
ing to impaired walking function. A month later the patient still 
suffered from invalidating polyneuropathy, defined as a grade 
3 nervous system disorder using the common terminology cri-
teria for adverse events v3.0 (CTCAE).
Clinical examination revealed extensive sensory and mo-
tor neuropathy, primarily in the lower extremities. Spinal fluid 
examination, blood samples and magnetic resonance imaging 
(MRI) scan were normal. Nerve conduction studies (NCSs) 
revealed sensorimotor axonal polyneuropathy, predominantly 
in the lower extremities (Table 1). The patient’s total levels of 
arsenic (including bi-products of metabolization) in urine and 
blood 2 months after the last ATO dose was administered, were 
within the reference range of a population with a high intake 
of fish and shellfish. Her spouse, who shared the same lifestyle 
and diet as the patient, had markedly lower urine and blood ar-
senic levels, and were within the reference range of the general 
population [6]. Especially the levels of dimethylarsenic acid 
(DMA) were higher in the urine and blood of the patient, with 
levels of 21.2 µg/L and 1.57 µg/L, respectively. The spouse 
had levels of DMA in urine and blood at 2.84 µg/L and < 1 
µg/L, respectively, which can be seen in Table 1.
Eight months following end of ATO treatment, the patient 
continues to suffer from peripheral neuropathy. While motor 
functions have slightly improved, complete loss of sensation 
peripherally on all extremities is persisting. The patient is still 
in CR and MRD negative without any further treatment.
Discussion
We have presented a case of a patient treated with ATO and ATRA 
for APL, who developed severe and invalidating arsenic-induced 
CTCAE grade 3 peripheral sensorimotor axonal neuropathy. In 
the AML-17 trial with a total of 116 patients, no peripheral neu-
ropathy was reported [7]. The patient followed the treatment reg-
imen from the AML-17 trial but had to discontinue ATO after the 
first consolidation course of four planned consolidation courses. 
Arsenic is a highly toxic compound, that has been used in medi-
cal applications for centuries and symptoms of intoxication are 
well described [2, 3]. Peripheral neuropathy and skin rash led 
to suspicion of ATO intoxication in the case presented, and are 
among the most frequent signs of intoxication. Also, the patient 
had NCS results consistent with severe axonal polyneuropathy, 
which is a rarely reported side effect to ATO treatment [5].
A study from Shen et al included 15 patients with relapsed 
APL treated with ATO in dosages of 10 mg/day until CR, with 
total induction dosages between 280 and 540 mg. In the study, 
ATO was discontinued for 30 days after obtaining CR. After-
wards a consolidation therapy of 10 mg ATO/day was adminis-
tered for 28 days. A total (induction and consolidation) amount 
of ATO between 580 and 840 mg was administered. No signs of 
peripheral neuropathy were reported [8]. In a study from Soig-
net et al of 34 patients treated with ATO for relapse of APL, 
the induction therapy was administered with a dose of 0.15 mg/
kg/day until remission or a total of 60 doses. Afterwards, one 
consolidation treatment of 0.15 mg/kg for 25 doses over a maxi-
mum of 35 days was given. Seventeen patients reported CTCAE 
grade 1 peripheral neuropathy and one patient reported CTCAE 
grade 3 peripheral neuropathy, reported as impaired fine motor 
skills and gait disturbance. The treatment was discontinued, and 
the neuropathy spontaneously improved within 18 days [9]. Fi-
nally, Iland et al reported one patient suffering from peripheral 
neuropathy in a study of 124 patients treated with ATRA, idaru-
bicin and ATO (0.15 mg/kg daily) as initial therapy [10].
Conclusions
As patients with APL are now primarily treated with so-called 
chemo-free ATRA-ATO regimens, the question remains why 
some patients develop peripheral sensorimotor polyneuropa-
thy and whether this to some degree is reversible, as the mech-
anism of toxicity is not well understood. Clinicians and health 
care professionals treating APL patients should be aware of 
this potential adverse side effect, and continuously monitoring 
of side effects must include specific evaluation of neurological 
symptoms and prompt intervention when evident. Dose reduc-
tion or stop of ATO treatment should be considered in patients 
displaying signs of peripheral neuropathy.
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